Biotech Values

[genisi]

Xarelto® (rivaroxaban) has been approved by the European Commission for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) after an Acute Coronary Syndrome (ACS)

http://press.healthcare.bayer.com/en/press/news-details-page.php/15050/2013-0292